StocksMedium•10 November 2026•
1 min read
Arbutus Biopharma Reports Q3 2026 Earnings Beat Despite Revenue Miss
Key Facts
1Arbutus Biopharma reported GAAP EPS of $0.30, beating analyst estimates by $0.32.
2The company's revenue reached $0.3M, missing analyst estimates by $0.7M.
Arbutus Biopharma reported GAAP EPS of $0.30 for the third quarter of 2026, beating analyst estimates by $0.32. Seeking Alpha reported that the company's revenue reached $0.3 million, which missed expectations by $0.7 million.
ABUS closed at $3.72 on November 9, 2026, prior to the release of these financial results for the period ending September 2026. The performance indicates mixed financial outcomes, as the significant earnings per share beat contrasted with the revenue shortfall.